| Identification | Back Directory | [Name]
5’-O-DMTr-2’-OMeU-methyl phosphonamidite | [CAS]
191786-64-8 | [Synonyms]
5’-O-DMTr-2’-OMeU-methylphosphonamidite
5’-O-DMTr-2’-OMeU-methyl phosphonamidite
5'-O-DMTr-2'-O-methyluridine-3'-O-(P-methyl-N,N-diisopropylamino)phosphomidite
Uridine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-O-methyl-, 3'-[P-methyl-N,N-bis(1-methylethyl)phosphonamidite] (9CI)
5’-O-DMTr-2’-OMeU-methyl phosphonamidite, 5’-O-DMTr-2’-O-methyluridine-3’-O-(P-methyl-N,N-diisopropylamino) phosphonamidite | [Molecular Formula]
C38H48N3O8P | [MOL File]
191786-64-8.mol | [Molecular Weight]
705.79 |
| Hazard Information | Back Directory | [Uses]
5’-O-DMTr-2’-OMeU-methyl phosphonamidite is a purine nucleoside analog. Purine nucleoside analogs have broad antitumor activity targeting indolent lymphoid malignancies. Anticancer mechanisms in this process rely on inhibition of DNA synthesis, induction of apoptosis, etc[1]. | [References]
[1] Robak T, Robak P. Purine nucleoside analogs in the treatment of rarer chronic lymphoid leukemias. Curr Pharm Des. 2012;18(23):3373-88. DOI:10.2174/138161212801227005 |
|
| Company Name: |
NewCan Biotech Limited
|
| Tel: |
+86-0571-86912261 +86-15658003402 |
| Website: |
https://www.newcanbio.com/ |
|